Published in Lab Law Weekly, September 28th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Miraculins.
Report 1: V: MOM) (the "Company"), a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, today announces a non-brokered private placement offering (the "Offering") of up to 1,250,000 units ("Units") at a price of $0.40 per Unit for gross proceeds of up to $500,000. Each Unit will be comprised of one common share of the Company (a "Share") and one half of one Share purchase warrant (a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.